Lung Tumor Cells
Lung cancer remains one of the most prevalent and lethal malignancies worldwide, primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). These tumors are characterized by significant genetic diversity, involving key driver mutations such as EGFR, KRAS, and ALK rearrangements.
Our lung tumor cell line collection offers a comprehensive range of in vitro models, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, as well as aggressive SCLC models. These cell lines are essential tools for studying lung cancer pathogenesis, identifying novel biomarkers, and evaluating the efficacy of targeted therapies and immunotherapies.
Comprehensive Genotyped Validated High-Quality
Key Features & Expertise
Our lung tumor cell lines are distinguished by their molecular depth and experimental versatility:
Extensive Pathological Diversity
- Full coverage of NSCLC subtypes: Adenocarcinoma, Squamous Cell, and Large Cell Carcinoma
- Highly aggressive SCLC models characterized by rapid growth and neuroendocrine features
- Rare lung tumor models and drug-resistant variants for specialized oncology research
Defined Molecular & Genetic Profiles
- Characterized driver mutations including EGFR (L858R, T790M), KRAS (G12C/D/V), and ALK/ROS1 fusions
- Profiles for tumor suppressors such as TP53, PTEN, and STK11
- Data on PD-L1 expression levels to support immunotherapy and checkpoint inhibitor research
Stringent Quality Assurance
- STR authentication for every cell line to ensure genetic integrity
- Rigorous screening for Mycoplasma, bacteria, and viral contaminants
- Optimized protocols for 2D culture, 3D spheroids, and xenograft applications
FAQ
What are the main differences between NSCLC and SCLC cell lines?
NSCLC cell lines (85% of lung cancers) typically grow slower and represent adenocarcinoma or squamous cell carcinoma. SCLC cell lines are more aggressive, show rapid doubling times, and often exhibit neuroendocrine markers and a higher propensity for early metastasis.
Do you provide cell lines with specific EGFR or KRAS mutations?
Yes. Our collection includes cell lines with specific mutations such as EGFR exon 19 deletions, L858R point mutations, and KRAS G12C, which are critical for studying sensitivity or resistance to TKIs (Tyrosine Kinase Inhibitors).
Can these cell lines be used for PD-L1 and immunotherapy studies?
Absolutely. Many of our lung tumor cell lines have documented PD-L1 expression levels, making them ideal for co-culture assays with T-cells or testing anti-PD-1/PD-L1 therapeutic agents.
How do I choose between an adenocarcinoma and a squamous cell carcinoma model?
The choice depends on your research focus. Adenocarcinoma models are often preferred for studying mucus-secreting epithelial pathways and EGFR/ALK targeted therapies, while squamous cell models are better for investigating smoking-related oncogenesis and FGFR-related signaling.
Are the cell lines suitable for 3D culture or organoid formation?
Yes, many of our lung tumor cell lines, are validated for 3D culture and high-throughput screening. They can form stable spheroids that better mimic the in vivo tumor microenvironment.